110 related articles for article (PubMed ID: 16397033)
1. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
[TBL] [Abstract][Full Text] [Related]
2. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
3. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
4. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
5. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer.
Bartlett JM; Brawley D; Grigor K; Munro AF; Dunne B; Edwards J
J Pathol; 2005 Mar; 205(4):522-9. PubMed ID: 15685688
[TBL] [Abstract][Full Text] [Related]
6. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.
Diallo JS; Aldejmah A; Mouhim AF; Péant B; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2007 Dec; 13(23):7044-52. PubMed ID: 18056181
[TBL] [Abstract][Full Text] [Related]
7. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
Daneshmand S; Quek ML; Lin E; Lee C; Cote RJ; Hawes D; Cai J; Groshen S; Lieskovsky G; Skinner DG; Lee AS; Pinski J
Hum Pathol; 2007 Oct; 38(10):1547-52. PubMed ID: 17640713
[TBL] [Abstract][Full Text] [Related]
8. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.
Lee CM; Shrieve DC; Zempolich KA; Lee RJ; Hammond E; Handrahan DL; Gaffney DK
Gynecol Oncol; 2005 Nov; 99(2):415-21. PubMed ID: 16157365
[TBL] [Abstract][Full Text] [Related]
9. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence.
Hernes E; Fosså SD; Berner A; Otnes B; Nesland JM
Br J Cancer; 2004 Jan; 90(2):449-54. PubMed ID: 14735192
[TBL] [Abstract][Full Text] [Related]
10. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
11. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
12. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
13. Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer.
Ohara S; Oue N; Matsubara A; Mita K; Hasegawa Y; Hayashi T; Usui T; Amatya VJ; Takeshima Y; Kuniyasu H; Yasui W
Cancer Sci; 2008 Aug; 99(8):1570-7. PubMed ID: 18754868
[TBL] [Abstract][Full Text] [Related]
14. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
15. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
[TBL] [Abstract][Full Text] [Related]
16. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer.
Tambo M; Higashihara E; Terado Y; Nutahara K; Okegawa T
Int J Urol; 2009 Apr; 16(4):369-74. PubMed ID: 19207111
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
19. Bad expression influences time to androgen escape in prostate cancer.
Teo K; Gemmell L; Mukherjee R; Traynor P; Edwards J
BJU Int; 2007 Sep; 100(3):691-6. PubMed ID: 17542986
[TBL] [Abstract][Full Text] [Related]
20. High expression of HER3 is associated with a decreased survival in gastric cancer.
Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
